IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug atrasentan aims to slow kidney disease in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests whether the drug atrasentan can slow kidney function loss in 404 people with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants receive either atrasentan or a placebo, and researchers measure changes in protein in the urine an…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New shot shows promise in slowing kidney disease
Disease control OngoingThis phase 3 study tests BION-1301 (Zigakibart) in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants receive either the drug or a placebo as a shot every 2 weeks for 2 years. The main goal is to see if the drug helps preserve kidney f…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
New drug could slow kidney damage in IgA nephropathy patients
Disease control OngoingThis phase 3 study tests a drug called atacicept in 376 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if atacicept can reduce protein in the urine and slow the loss of kidney function compared to a placebo. Participants must hav…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC
-
New drug shows promise in slowing kidney disease progression
Disease control OngoingThis study tests an oral drug called atrasentan in 103 adults with kidney diseases that cause protein leakage in urine, such as IgA nephropathy and FSGS. The goal is to see if atrasentan can lower protein levels and protect kidney function over 12 to 30 weeks. Participants must a…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 08, 2026 13:13 UTC